Search Page

1

Cite

Share

Efavirenz dosing: influence of drug metabolizing enzyme polymorphisms and concurrent tuberculosis treatment.

Gengiah TN, Botha JH, Yende-Zuma N, Naidoo K, Abdool Karim SS. Gengiah TN, et al. Antivir Ther. 2015;20(3):297-306. doi: 10.3851/IMP2877. Epub 2015 Oct 15. Antivir Ther. 2015. PMID: 25318122

Cite

Share

2

Cite

Share

Pharmacological interactions between rifampicin and antiretroviral drugs: challenges and research priorities for resource-limited settings.

Semvua HH, Kibiki GS, Kisanga ER, Boeree MJ, Burger DM, Aarnoutse R. Semvua HH, et al. Ther Drug Monit. 2015 Feb;37(1):22-32. doi: 10.1097/FTD.0000000000000108. Ther Drug Monit. 2015. PMID: 24943062 Review.

Cite

Share

3

Cite

Share

Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study.

Semvua HH, Mtabho CM, Fillekes Q, van den Boogaard J, Kisonga RM, Mleoh L, Ndaro A, Kisanga ER, van der Ven A, Aarnoutse RE, Kibiki GS, Boeree MJ, Burger DM. Semvua HH, et al. Antivir Ther. 2013;18(1):105-13. doi: 10.3851/IMP2413. Epub 2012 Oct 5. Antivir Ther. 2013. PMID: 23043067 Clinical Trial.

Cite

Share

4

Cite

Share

The role of genetic polymorphisms in cytochrome P450 and effects of tuberculosis co-treatment on the predictive value of CYP2B6 SNPs and on efavirenz plasma levels in adult HIV patients.

Bienvenu E, Swart M, Dandara C, Ashton M. Bienvenu E, et al. Antiviral Res. 2014 Feb;102:44-53. doi: 10.1016/j.antiviral.2013.11.011. Epub 2013 Dec 5. Antiviral Res. 2014. PMID: 24316028

Cite

Share

5

Cite

Share

Mycobacterium haemophilum bone and joint infection in HIV/AIDS: case report and literature review.

Cross GB, Le Q, Webb B, Jenkin GA, Korman TM, Francis M, Woolley I. Cross GB, et al. Int J STD AIDS. 2015 Nov;26(13):974-81. doi: 10.1177/0956462414565403. Epub 2015 Jan 10. Int J STD AIDS. 2015. PMID: 25577597 Review.

Cite

Share

6

Cite

Share

Impact of CYP polymorphisms, ethnicity and sex differences in metabolism on dosing strategies: the case of efavirenz.

Naidoo P, Chetty VV, Chetty M. Naidoo P, et al. Eur J Clin Pharmacol. 2014 Apr;70(4):379-89. doi: 10.1007/s00228-013-1634-1. Epub 2014 Jan 5. Eur J Clin Pharmacol. 2014. PMID: 24390631 Review.

Cite

Share

7

Cite

Share

Evaluation of CYP2B6 Induction and Prediction of Clinical Drug-Drug Interactions: Considerations from the IQ Consortium Induction Working Group-An Industry Perspective.

Fahmi OA, Shebley M, Palamanda J, Sinz MW, Ramsden D, Einolf HJ, Chen L, Wang H. Fahmi OA, et al. Drug Metab Dispos. 2016 Oct;44(10):1720-30. doi: 10.1124/dmd.116.071076. Epub 2016 Jul 15. Drug Metab Dispos. 2016. PMID: 27422672

Cite

Share

8

Cite

Share

Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosis.

Haas DW, Mngqibisa R, Francis J, McIlleron H, Robinson JA, Kendall MA, Baker P, Mawlana S, Badal-Faesen S, Angira F, Omoz-Oarhe A, Samaneka WP, Denti P, Cohn SE; AIDS Clinical Trials Group A5338 Study Team. Haas DW, et al. Pharmacogenet Genomics. 2022 Jan 1;32(1):24-30. doi: 10.1097/FPC.0000000000000448. Pharmacogenet Genomics. 2022. PMID: 34369424 Clinical Trial.

Cite

Share

9

Cite

Share

Plasma concentrations, efficacy and safety of efavirenz in HIV-infected adults treated for tuberculosis in Cambodia (ANRS 1295-CIPRA KH001 CAMELIA trial).

Borand L, Madec Y, Laureillard D, Chou M, Marcy O, Pheng P, Prak N, Kim C, Lak KK, Hak C, Dim B, Nerrienet E, Fontanet A, Sok T, Goldfeld AE, Blanc FX, Taburet AM. Borand L, et al. PLoS One. 2014 Mar 7;9(3):e90350. doi: 10.1371/journal.pone.0090350. eCollection 2014. PLoS One. 2014. PMID: 24608960 Free PMC article. Clinical Trial.

Cite

Share

10

Cite

Share

Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients.

Habtewold A, Aklillu E, Makonnen E, Amogne W, Yimer G, Aderaye G, Bertilsson L, Owen JS, Burhenne J. Habtewold A, et al. J Clin Pharmacol. 2016 Dec;56(12):1538-1549. doi: 10.1002/jcph.756. Epub 2016 May 29. J Clin Pharmacol. 2016. PMID: 27125860 Clinical Trial.

Cite

Share